Seneca Valley Virus 3C(pro) Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy

The oncolytic picornavirus Seneca Valley Virus (SVV-001) demonstrates anti-tumor activity in models of small cell lung cancer (SCLC), but may ultimately need to be combined with cytotoxic therapies to improve responses observed in patients. Combining SVV-001 virotherapy with a peptide prodrug activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Miles, Linde A., Brennen, W. Nathaniel, Rudin, Charles M., Poirier, John T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466507/
https://www.ncbi.nlm.nih.gov/pubmed/26069962
http://dx.doi.org/10.1371/journal.pone.0129103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466507/
https://www.ncbi.nlm.nih.gov/pubmed/26069962
http://dx.doi.org/10.1371/journal.pone.0129103

Ejemplares similares